Ticker Symbol: IMGN
Immunogen, Inc.
$5.79 - 02-12-2024 4 p.m. ET
Exchange: NASDAQ
Country:
US
Currency:
USD
Asset
Type: Common Stock
CIK:0000855654
Company Profile
ImmunoGen is developing the next generation of antibody-drug conjugates to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, the company aims to disrupt the progression of cancer and offer its patients more good days.
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Standard Industrial Classification Code (SIC code): 2834
Address: 84 State St
Website: www.immunogen.com
CEO: Mark Enyedy
Tags:
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Pricing
Last Updated: October 3, 2023 03:00 PM EST
Previous Close: $15.80
Change:
$0.03
(
0.19%)
Days Range: $15.53 - $16.05
Beta: 0.64
52wk. High: $20.69
52wk. Low: $3.61
Ytd. Change 218.13%
50 Day Moving Average: $15.18
200 Day Moving Average: $14.46
Shares Outstanding: 248943426
Valuation
Market Cap: 393.3B
PE Ratio: -22.36
EPS (TTM): -0.7067
Dividends
Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A